Illumina Picked Solexa After Mulling Internal Development, Other Next-Gen Shops | GenomeWeb
NEW YORK (GenomeWeb News) — Soon after Illumina last week disclosed its plans to acquire Solexa for $600 million in stock, Illumina’s CEO spent the rest of the week explaining to investors and employees how the deal emerged, and how the two companies plan to integrate their technologies and businesses.
 
After the merger, expected to close by the end of next March, Solexa will become a sequencing business unit of Illumina. Solexa currently employs 175people and Illumina had 375staffers as of January.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.